Immunocore is set to learn this week whether its investigational immunotherapy and lead drug candidate, tebentafusp, is on track to receive EU-wide marketing approval.
Tebentafusp, intended for the treatment of metastatic uveal melanoma, seems to have breezed through the EU regulatory evaluation process, having been accepted for fast-track review just last August